Quantcast

Latest EntreMed Inc. Stories

2014-06-13 08:23:53

Common stock to begin trading under "CASI" on June 16, 2014 ROCKVILLE, Md., June 13, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that at its annual meeting of stockholders held on June 12, 2014, stockholders voted in favor of changing the company's corporate name to CASI Pharmaceuticals, Inc. The name change will occur on June 16, 2014 with the...

2014-06-03 08:31:33

ROCKVILLE, Md., June 3, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that Franklin C. Salisbury, Jr. has joined the Company's Board of Directors. http://photos.prnewswire.com/prnvar/20010620/ENMDLOGO Since 1998, Mr. Salisbury has served as president of the National Foundation for Cancer Research (NFCR), an organization that supports healthcare...

2014-05-19 08:27:27

ROCKVILLE, Md., May 19, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today two poster presentations on ENMD-2076 at the American Society of Clinical Oncology Annual Meeting for two of its trials currently in progress. ENMD-2076 is currently in Phase 2 advanced soft tissue sarcoma and Phase 2 ovarian clear cell carcinoma, trials at Princess Margaret Cancer...

2014-05-15 08:31:37

ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20010620/ENMDLOGO The Company reported a net loss for the first quarter of 2014 of ($1.5 million), or ($0.05) per share, compared with a net loss of ($1.1 million), or ($0.05) per share,...

2014-03-21 08:24:23

ROCKVILLE, Md., March 21, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three and 12 months ended December 31, 2013. http://photos.prnewswire.com/prnvar/20010620/ENMDLOGO The Company reported a net loss of ($1.3 million), or ($0.05) per share for the three months ended December 31, 2013. This compares with net loss of ($0.4...

2014-01-13 08:26:50

To Expand Clinical Trial for Advanced Ovarian Clear Cell Carcinoma ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China's Food and Drug...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related